Imatinib Denk

Imatinib, the active ingredient in Imatinib Denk, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Denk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib Denk is a targeted therapy that interferes with specific tyrosine‑kinase driven cancers. - Chronic myeloid leukemia (CML): suppresses BCR‑ABL driven proliferation and improves long‑term survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): induces remission by blocking leukemic signaling. - Gastrointestinal stromal tumor (GIST): inhibits c‑KIT and PDGFR activity to control tumor growth.

Adverse reactions to Imatinib Denk vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often of the ankles. - Fatigue: generalized tiredness. - Muscle cramps: intermittent skeletal muscle discomfort.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Cardiotoxicity: congestive heart failure or reduced ejection fraction. - Severe neutropenia: marked decrease in white blood cells increasing infection risk.

Before prescribing Imatinib Denk, clinicians should consider several safety aspects. - Pregnancy: contraindicated (Category D) – avoid use in pregnant patients. - Breastfeeding: not recommended; drug may be excreted in milk. - Hepatic impairment: assess liver function and adjust monitoring. - Cardiac function: evaluate baseline cardiac status, especially in patients with prior heart disease. - Drug interactions: review concomitant medications for CYP3A4 modulators. - Store at below 25°C: keep in original container, protect from moisture and direct sunlight.

Imatinib Denk can alter or be altered by other medicines; careful review is required.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce plasma concentrations. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase exposure and toxicity.

Moderate Interactions (Monitor Closely): - Acid‑reducing agents (e.g., proton pump inhibitors, antacids): may affect absorption. - Anticoagulants (e.g., warfarin): may require INR monitoring. - Vaccines: live attenuated vaccines should be avoided during therapy.